Stock listing

BMV:ARDX Ardelyx, Inc. Acciones

Mexican listing (BMV) of Ardelyx, Inc. · home listing NASDAQ:ARDX

Follow Ardelyx, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ARDX

$2.99 USD -0.13 (-4.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ARDX

Past year -46.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.95 – $3.08 USDNov 20, 2026
Volume
6.20M sharesNov 20, 2026
Market cap
$751.6M USDAt the close on Nov 20, 2026 · price × 251.4M shares outstanding
52-week range
$2.80 – $8.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$14.80M USDMedian day 4.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Ardelyx, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ARDX · Home$2.99 USD-0.13 (-4.2%)6,200,407$3.01$3.08$2.95$3.12Close on Nov 20, 2026
Frankfurt:41X€2.76 EUR-0.06 (-2.1%)—€2.76€2.76€2.76€2.82Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARDX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.99-0.13-4.2%$3.01$3.08$2.956,200,407
$3.12-0.06-1.9%$3.23$3.26$3.0854,746,149
$3.18+0.11+3.6%$3.08$3.19$3.054,393,736
$3.07-0.02-0.6%$3.09$3.12$3.043,795,808
$3.09-0.03-1.0%$3.15$3.15$3.052,380,472
$3.12-0.01-0.3%$3.15$3.165$3.014,033,058
$3.13+0.12+4.0%$3.04$3.15$2.953,292,457
$3.01+0.08+2.7%$2.90$3.04$2.905,466,005
$2.93+0.05+1.7%$2.91$3.02$2.806,448,072
$2.88-0.11-3.7%$2.99$2.99$2.845,441,741
$2.99-0.30-9.1%$3.27$3.30$2.967,750,986
$3.29+0.26+8.6%$3.41$3.41$3.08510,583,598
$3.030.000.0%$3.06$3.10$3.026,118,737
$3.030.000.0%$3.00$3.085$2.9754,602,633
$3.03-0.07-2.3%$3.09$3.119$2.963,625,598
$3.100.000.0%$3.12$3.16$3.0752,549,379
$3.10+0.10+3.3%$2.98$3.11$2.9553,939,570
$3.000.000.0%$3.01$3.04$2.974,856,285
$3.00-0.08-2.6%$3.08$3.11$2.994,996,880
$3.08-0.12-3.8%$3.17$3.20$3.024,814,624
$3.20+0.07+2.2%$3.13$3.22$3.112,723,800
$3.13-0.08-2.5%$3.23$3.23$3.123,017,464
$3.21+0.12+3.9%$3.10$3.25$3.103,964,190
$3.090.000.0%$3.09$3.13$3.053,227,276
$3.09-0.18-5.5%$3.26$3.265$3.085,775,900
$3.27+0.08+2.5%$3.24$3.35$3.194,072,100
$3.19+0.07+2.2%$3.10$3.25$3.065,822,300
$3.12-0.11-3.4%$3.20$3.205$3.096,872,700
$3.23-0.05-1.5%$3.28$3.28$3.183,537,400
$3.28+0.01+0.3%$3.26$3.30$3.212,356,900
$3.27+0.01+0.3%$3.23$3.30$3.186,538,200
$3.26-0.05-1.5%$3.26$3.35$3.225,388,100
$3.31-0.08-2.4%$3.39$3.408$3.235,815,800
$3.39+0.05+1.5%$3.35$3.42$3.284,252,900
$3.34-0.04-1.2%$3.38$3.40$3.294,092,100
$3.38-0.04-1.2%$3.46$3.46$3.3554,107,200
$3.42+0.03+0.9%$3.43$3.46$3.3654,411,900
$3.39-0.02-0.6%$3.42$3.435$3.314,433,800
$3.41-0.01-0.3%$3.40$3.44$3.3753,318,100
$3.42-0.03-0.9%$3.47$3.485$3.402,126,100
$3.45-0.03-0.9%$3.47$3.49$3.4153,231,500
$3.48-0.14-3.9%$3.60$3.62$3.426,279,600
$3.62+0.12+3.4%$3.54$3.63$3.473,988,100
$3.50+0.08+2.3%$3.455$3.525$3.372,833,500
$3.42+0.04+1.2%$3.38$3.445$3.336,434,200
$3.38-0.01-0.3%$3.44$3.495$3.344,228,700
$3.39-0.01-0.3%$3.40$3.43$3.345,377,800
$3.40-0.12-3.4%$3.52$3.521$3.385,095,900
$3.52-0.06-1.7%$3.60$3.60$3.514,364,000
$3.58-0.04-1.1%$3.65$3.68$3.565,690,300
$3.62-0.18-4.7%$3.77$3.78$3.614,040,500
$3.80+0.03+0.8%$3.73$3.915$3.694,470,500
$3.77-0.01-0.3%$3.76$3.80$3.712,958,700
$3.78+0.07+1.9%$3.68$3.78$3.682,981,800
$3.71-0.09-2.4%$3.80$3.83$3.6853,470,500
$3.80+0.04+1.1%$3.75$3.835$3.7253,913,600
$3.76-0.02-0.5%$3.78$3.815$3.753,645,300
$3.78-0.03-0.8%$3.80$3.81$3.683,801,700
$3.81-0.01-0.3%$3.81$3.90$3.755,133,400
$3.82-0.01-0.3%$3.83$3.86$3.792,285,900
$3.83+0.05+1.3%$3.845$3.89$3.7752,914,300
$3.78+0.04+1.1%$3.75$3.925$3.753,428,400
$3.74-0.15-3.9%$3.88$3.89$3.7255,210,900
$3.89-0.01-0.3%$3.92$3.97$3.882,878,900
$3.90-0.13-3.2%$4.04$4.067$3.864,565,300

Splits

1 split · NASDAQ:ARDX · every price before a split is adjusted for it

DayRatioWhat
4-for-1Split
Ticker
BMV:ARDX
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BMV
Currency
MXN

What changed lately

Latest news

All Ardelyx, Inc. news

Ardelyx, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
29 in the last 12 months · 203 in all · newest Nov 10, 2026 · oldest 2019
Calls
16 calls with a replay · 16 with a transcript · latest Nov 3, 2026
Decks
20 decks · latest Nov 3, 2026

Where Ardelyx, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARDX · Home listingNASDAQUnited StatesUSD
gettex:41XgettexGermanyEUR
LS Exchange:A116X0LS ExchangeGermanyEUR
Tradegate:41XTradegateGermanyEUR
BMV:ARDX · This pageBMVMexicoMXN
Frankfurt:41XFrankfurtGermanyEUR
Lang & Schwarz:A116X0Lang & SchwarzGermanyEUR
BIVA:ARDXBIVAMexicoMXN
BOATS:ARDXBOATSUnited StatesUSD
BX Swiss:41XBX SwissSwitzerlandCHF
Dusseldorf:41XDusseldorfGermanyEUR
Hamburg:41XHamburgGermanyEUR
Munich:41XMunichGermanyEUR
Stuttgart:41XStuttgartGermanyEUR

Valuation

EV/sales 1.5× against a median of 2.6×: 3rd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$718.6M USD
P/E
Loss
EV/sales
1.5×
EV/EBITDA
Negative EBITDA
Price/book
4.6×
Gross margin
94.3%
Operating margin
−7.7%
Net margin
−11.8%
Debt to equity
1.5×
Beta vs S&P 500
0.88

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Ardelyx, Inc. · NASDAQ:ARDXUS$751.6MUS$718.6Mn/a1.5×n/a4.6×−11.8%1.5×0.88
Zhejiang Ausun Pharmaceutical Co., Ltd. Class A · SSE:603229US$780.2MUS$640.1Mn/a5.6×n/a2.3×−0.6%0.0×n/a
Jinghua Pharmaceutical Group Co., Ltd. Class A · SZSE:002349US$774.6MUS$606.2M22.2×2.7×n/a1.8×15.7%0.0×n/a
Dezhan Healthcare Co., Ltd. Class A · SZSE:000813US$768.0MUS$680.7Mn/a13.0×n/a1.1×−111.1%0.0×n/a
Knight Therapeutics, Inc. · TSX:GUDUS$763.1MUS$683.3M68.5×1.7×10.5×1.4×2.8%0.0×0.33
Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A · SZSE:002424US$757.0MUS$728.7Mn/a2.1×n/a1.6×−5.5%0.0×n/a
Luye Pharma Group Ltd. · HKEX:2186US$751.7MUS$1.02B8.1×1.1×3.3×0.3×9.8%0.8×n/a
Genomma Lab Internacional SAB de CV Class B · BMV:LAB/BUS$740.5MUS$953.0M8.3×1.1×4.8×1.2×10.0%0.6×n/a
Bliss GVS Pharma Limited · NSE:BLISSGVSUS$735.1MUS$716.7M42.3×6.2×28.1×5.3×15.0%0.0×n/a
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A · SSE:603998US$732.2MUS$694.9M14.9×2.5×n/a2.7×17.4%0.0×n/a
Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A · SZSE:002082US$729.9MUS$658.8Mn/a5.0×n/a1.9×−20.2%0.1×n/a
Median of the othersUS$754.3MUS$689.1M18.6×2.6×7.6×1.7×6.3%0.0×0.33

Forecasts

10 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
12.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.20 · 7 analysts
Revenue, year to Dec 2026
482.2M · 11 analysts

Team and board

Officers

OfficerRole
Mike RaabPresident & Chief Executive Officer
Sue HohenleitnerChief Financial Officer
Felecia EttenbergChief Legal Officer
Caitlin LowieArdelyx Investor Relations and Corporate
Lindsey ManuelAssociate Director, Corporate Communications
Lisa CaperelliSVP, Investor Relations & Corporate Communications
Jamie BradyChief Human Resources Officer
John BishopChief Technical and Quality Officer
Laura WilliamsChief Patient Officer Emeritus
Mike KelliherChief Business Officer
Rajani DinavahiChief Medical Officer

Board

DirectorRole
David MottChairman
Merdad ParseyDirector
Mike RaabPresident & Chief Executive Officer
Muna BhanjiDirector
Onaiza Cadoret-ManierDirector
Richard RodgersDirector
Robert BazemoreDirector
William A. BertrandDirector

Events

Calls

CallWhenStatus
Ardelyx (NASDAQ:ARDX) Q3 2026 Earnings CallTue, Nov 03, 2026 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q2 2026 Earnings CallThu, Aug 06, 2026 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q1 2026 Earnings CallThu, Apr 30, 2026 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q4 2025 Earnings CallThu, Feb 19, 2026 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q3 2025 Earnings CallThu, Oct 30, 2025 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q2 2025 Earnings CallMon, Aug 04, 2025 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q1 2025 Earnings CallThu, May 01, 2025 · 4:00 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q4 2024 Earnings CallThu, Feb 20, 2025 · 8:00 AM ETReplay
Ardelyx (NASDAQ:ARDX) Q3 2024 Earnings CallThu, Oct 31, 2024 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
All 16 calls
CallWhenStatus
Ardelyx (NASDAQ:ARDX) Q1 2024 Earnings CallThu, May 02, 2024 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q4 2023 Earnings CallThu, Feb 22, 2024 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q3 2023 Earnings CallTue, Oct 31, 2023 · 8:00 AM ETReplay
Ardelyx (NASDAQ:ARDX) Q4 2022 Earnings CallThu, Mar 02, 2023 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Ardelyx (NASDAQ:ARDX) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 3, 2026 · After close+8.6%
Q2 2026Aug 6, 2026 · After close−17.9%
Q1 2026Apr 30, 2026 · After close+8.7%
Q4 2025Mar 11, 2026−7.5%
Q3 2025Oct 30, 2025 · After close+21.0%
Q2 2025Aug 4, 2025 · After close+16.9%
Q1 2025May 1, 2025 · After close−24.5%
Q4 2024Feb 20, 2025 · Before open−10.1%
Q3 2024Oct 31, 2024 · After close+3.8%
Q2 2024Aug 1, 2024 · After close+10.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+28.4%
Q4 2023Feb 22, 2024 · After close−1.6%
Q3 2023Oct 31, 2023 · Before open+9.1%
Q2 2023Aug 2, 2023 · Before open+5.2%
Q1 2023May 3, 2023 · After close+0.4%
Q4 2022Mar 2, 2023 · After close+32.2%
Q3 2022Nov 3, 2022 · After close0.0%
Q2 2022Aug 4, 2022 · After close+4.0%
Q1 2022May 5, 2022 · After close−3.3%
Q4 2021Feb 28, 2022 · After close−5.5%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings15 slidesNov 3, 2026
Q2 2026 Earnings PresentationEarnings18 slidesAug 6, 2026
Investor Presentation (August 2026)Investor deck30 slidesAugust 2026
Q1 2026 Earnings PresentationEarnings23 slidesApr 30, 2026
Q4 2025 Earnings PresentationEarnings27 slidesFeb 19, 2026
Q2 2025 Earnings PresentationEarnings22 slidesAug 4, 2025
Corporate Update (December 2019)Corporate update22 slidesDec 3, 2019
J.P. Morgan Healthcare Conference 2019Conference20 slidesJan 7, 2019
Corporate Update (October 2017)Corporate update26 slidesOct 11, 2017
Q2 2017 Earnings PresentationEarnings22 slidesAug 8, 2017
All 20 decks
DeckKindSlidesDate
Investor Presentation (June 2017)Investor deck20 slidesJun 22, 2017
JPMorgan 2017 Annual Healthcare ConferenceConference40 slidesJan 9, 2017
Technical Presentation (May 2015)Technical18 slidesMay 19, 2015
Investor Presentation (February 2015)Investor deck45 slidesFeb 9, 2015
Technical Presentation (2015)Technical14 slides2015
Technical Presentation (2015)Technical19 slides2015
Technical Presentation (November 2014)Technical12 slidesNov 14, 2014
Corporate Update (October 2014)Corporate update10 slidesOct 1, 2014
Investor Presentation (August 2014)Investor deck37 slidesAug 6, 2014
Technical Presentation (2014)Technical12 slides2014

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue407.3M333.6M124.5M52.2M10.1M7.57M5.28M2.61M42.0M24.0M
Cost of revenue39.5M50.6M17.8M4.12M1.00M145.0K600.0K466.0K8.40M1.29M
Gross profit364.7M283.1M106.7M48.0M9.10M7.43M4.68M2.14M33.6M22.7M
Research and development71.5M52.3M35.5M35.2M91.1M65.1M71.7M69.4M75.5M94.2M
Selling, general and administrative337.2M258.7M134.4M76.6M72.3M33.2M24.3M23.7M23.2M18.7M
Operating income-41.0M-27.9M-63.3M-63.8M-154.3M-90.8M-91.3M-90.9M-65.1M-112.9M
Depreciation and amortization3.06M2.06M1.29M1.14M2.81M2.54M2.50M2.70M2.60M1.30M
EBITDA-37.9M-25.9M-62.0M-62.6M-151.5M-88.2M-88.8M-88.2M-62.5M-111.6M
Interest expense20.1M13.0M4.95M3.40M4.50M5.10M5.73M3.53M00
Income before tax-60.6M-38.9M-65.5M-67.2M-158.2M-94.3M-94.6M-91.3M-63.2M-112.4M
Income tax969.0K266.0K547.0K8.00K4.00K2.00K303.0K4.00K1.18M29.0K
Net income-61.6M-39.1M-66.1M-67.2M-158.2M-94.3M-94.9M-91.3M-64.3M-112.4M
Earnings per share, basic-0.26-0.17-0.30-0.42-1.52-1.05-1.47-1.62-1.36-2.80
Earnings per share, diluted-0.26-0.17-0.30-0.42-1.52-1.05-1.47-1.62-1.36-2.80

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents68.0M64.9M21.5M96.1M72.4M91.0M181.1M78.8M75.4M74.6M
Short-term investments196.7M185.2M162.8M27.8M44.3M95.5M66.4M89.3M58.6M126.2M
Receivables71.8M57.7M22.0M7.73M502.0K0750.0K5.08M10.8M
Inventory123.1M91.2M49.5M28.3M0110
Current assets382.3M356.5M246.1M153.6M133.6M194.7M252.1M176.4M149.7M204.0M
Property, plant and equipment2.18M1.50M1.01M1.22M2.36M1.94M3.44M5.61M8.03M8.99M
Goodwill00
Total assets501.6M435.8M297.6M190.1M149.9M201.6M259.8M183.3M157.9M213.1M
Accounts payable19.2M16.0M11.1M10.9M4.28M5.63M2.19M1.15M3.93M5.63M
Current liabilities88.6M77.8M50.4M65.6M52.8M28.4M22.2M17.7M17.9M19.2M
Long-term debt202.8M150.9M49.8M46.6M48.8M49.2M00
Total debt202.8M150.9M49.8M26.7M32.3M50.8M50.0M52.0M
Total liabilities334.7M262.5M130.8M91.7M67.3M75.5M73.1M67.5M18.6M20.0M
Shareholders' equity166.9M173.3M166.8M98.3M82.6M126.1M186.7M115.8M139.3M193.2M
Shares outstanding244.4M238.0M232.5M198.6M130.2M93.6M88.8M62.5M47.5M47.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-42.5M-44.8M-89.7M-70.0M-152.6M-81.4M-76.5M-70.3M-65.2M-92.5M
Capital spending-1.49M-1.01M-344.0K-55.0K-1.87M-324.0K-325.0K-311.0K-2.35M-4.87M
Free cash flow-44.0M-45.8M-90.1M-70.1M-154.4M-81.8M-76.8M-70.6M-67.5M-97.4M
Cash from investing-8.96M-18.3M-131.2M18.4M50.9M-31.4M23.4M-29.9M65.3M-131.1M
Cash from financing54.5M106.6M146.3M75.3M83.0M22.8M155.5M103.6M685.0K191.2M
Dividends paid-25.9M-106.0K00
Share buybacks8.14M1.17M71.8M-106.0K22.9M155.1M54.3M685.0K191.2M
Change in cash3.07M43.5M-74.7M23.7M-18.6M-90.1M102.4M3.38M785.0K-32.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 17, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
8-K · Current reportAug 17, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 10, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026FinancingSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
144 · Notice of proposed saleJun 18, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
8-K · Current reportJun 17, 2026Management or board changeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedJun 17, 2026Other filingsSEC
144 · Notice of proposed saleJun 15, 2026Other filingsSEC
DEFA14A · Additional proxy materialMay 26, 2026Meeting noticeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
DEFA14A · Additional proxy materialMay 19, 2026Meeting noticeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
10-K · Annual reportFeb 19, 2026Annual reportSEC
8-K · Current reportFeb 19, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 12, 2026Big-stake noticeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
8-K · Current reportJan 8, 2026ResultsSEC
8-K · Current reportDec 17, 2025Management or board changeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
3 · Initial statement of ownershipNov 7, 2025Insider tradeSEC
S-3ASR · Registration statementNov 3, 2025Offer documentSEC
S-8 · Registration statement for employee plansNov 3, 2025Offer documentSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 28, 2025Big-stake noticeSEC
3 · Initial statement of ownershipOct 17, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 17, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 17, 2025Insider tradeSEC
8-K · Current reportOct 14, 2025Management or board changeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportAug 4, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
8-K · Current reportJul 3, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeJun 25, 2025Big-stake noticeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Management or board changeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
3 · Initial statement of ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
144 · Notice of proposed saleMay 2, 2025Other filingsSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
8-K · Current reportApr 29, 2025Management or board changeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
10-K · Annual reportFeb 20, 2025Annual reportSEC
8-K · Current reportFeb 20, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 12, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC

This page holds 200 of 1,013 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Ardelyx, Inc.’s releases · as of Oct 27, 2026

Common shares
251,372,553
Fully diluted
251,372,553

Fully diluted

LineSharesAs of
Common shares251,372,553Oct 27, 2026

Share count over time

CountShares
Oct 27, 2026251,372,553

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock28.4M11.3%US$97MSep 30, 2026
Vanguard20.5M8.2%US$70.2MSep 30, 2026
Rubric Capital Management LP13.9M5.5%US$47.6MSep 30, 2026
Millennium13.5M5.4%US$46MSep 30, 2026
State Street13.2M5.3%US$45.3MSep 30, 2026
Tang Capital Management LLC9.05M3.6%US$30.9MSep 30, 2026
Nomura8.86M3.5%US$30.3MSep 30, 2026
Geode Capital6.2M2.5%US$21.2MSep 30, 2026
Two Sigma5.42M2.2%US$18.5MSep 30, 2026
Caption Management, LLC4.11M1.6%US$14.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Invesco3.38M1.3%US$11.6MSep 30, 2026
Goldman Sachs3.25M1.3%US$11.1MSep 30, 2026
Susquehanna3.04M1.2%US$10.4MSep 30, 2026
Nuveen2.89M1.2%US$9.89MSep 30, 2026
Morgan Stanley2.59M1.0%US$8.84MSep 30, 2026
Qube Research & Technologies Ltd2.58M1.0%US$8.82MSep 30, 2026
Schwab2.48M0.98%US$8.47MSep 30, 2026
Rock Springs Capital Management LP2.37M0.94%US$8.1MSep 30, 2026
UBS2.33M0.93%US$7.97MSep 30, 2026
Northern Trust2.27M0.90%US$7.77MSep 30, 2026
Krensavage Asset Management, LLC1.82M0.72%US$6.21MSep 30, 2026
Bank of America1.81M0.72%US$6.21MSep 30, 2026
Schroders1.67M0.66%US$5.66MSep 30, 2026
ADAR1 Capital Management, LLC1.49M0.59%US$5.1MSep 30, 2026
Citadel1.39M0.55%US$4.74MSep 30, 2026
Citigroup Inc1.36M0.54%US$4.66MSep 30, 2026
Hennion & Walsh Asset Management, Inc.1.34M0.53%US$4.58MSep 30, 2026
Eversept Partners, LP1.31M0.52%US$4.46MSep 30, 2026
First Trust996K0.40%US$3.41MSep 30, 2026
AQR Capital Management LLC901K0.36%US$3.08MSep 30, 2026
Mackenzie894K0.36%US$3.06MSep 30, 2026
Squarepoint Ops LLC843K0.34%US$2.88MSep 30, 2026
BNP Paribas824K0.33%US$2.82MSep 30, 2026
Algert Global LLC771K0.31%US$2.64MSep 30, 2026
Sector Gamma As687K0.27%US$2.35MSep 30, 2026
BNY686K0.27%US$2.35MSep 30, 2026
Man Group plc586K0.23%US$2MSep 30, 2026
Panagora Asset Management Inc582K0.23%US$1.99MSep 30, 2026
Redmile Group, LLC524K0.21%US$1.79MSep 30, 2026
Swiss National Bank475K0.19%US$1.62MSep 30, 2026
Raymond James Financial Inc442K0.18%US$1.51MSep 30, 2026
State Of Wisconsin Investment Board432K0.17%US$1.48MSep 30, 2026
Hussman Strategic Advisors, Inc.420K0.17%US$1.44MSep 30, 2026
T. Rowe Price360K0.14%US$1.23MSep 30, 2026
Rafferty Asset Management, LLC316K0.13%US$1.08MSep 30, 2026
Clay Northam Wealth Management, LLC314K0.12%US$1.07MSep 30, 2026
Raiffeisen Bank International AG300K0.12%US$1.02MSep 30, 2026
Rhumbline Advisers299K0.12%US$1.02MSep 30, 2026
Virtus Investment Advisers, LLC296K0.12%US$1.01MSep 30, 2026
California State Teachers Retirement System273K0.11%US$935KSep 30, 2026

This page holds 50 of 216 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF7.42M3.0%US$37.8MJun 30, 2026
Vanguard Total Stock Market Index Fund7.4M2.9%US$37.8MJun 30, 2026
iShares Russell 2000 ETF6.36M2.5%US$32.4MJun 30, 2026
Nomura Small Cap Core Fund6.27M2.5%US$37.8MMay 29, 2026
Vanguard Extended Market Index Fund2.83M1.1%US$14.4MJun 30, 2026
Vanguard Strategic Equity Fund2.7M1.1%US$13.8MJun 30, 2026
Fidelity Small Cap Index Fund2.67M1.1%US$13.2MJul 31, 2026
iShares Russell 2000 Growth ETF2.26M0.90%US$11.5MJun 30, 2026
Janus Henderson Global Life Sciences Fund2.17M0.87%US$11.1MJun 30, 2026
Vanguard Explorer Fund1.51M0.60%US$7.46MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund1.26M0.50%US$7.59MMay 31, 2026
Vanguard Russell 2000 Index Fund1.23M0.49%US$7.44MMay 31, 2026
Nuveen Quant Small Cap Equity Fund1.19M0.47%US$5.9MJul 31, 2026
Schwab U.S. Small-Cap ETF1.17M0.46%US$7.04MMay 31, 2026
Invesco Biotechnology & Genome ETF1.12M0.45%US$5.55MJul 31, 2026
BlackRock Advantage Small Cap Core Fund923K0.37%US$5.57MMay 29, 2026
Nuveen Quant Small/Mid Cap Equity Fund921K0.37%US$4.56MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund782K0.31%US$3.99MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account747K0.30%US$3.81MJun 30, 2026
Vanguard Health Care Index Fund727K0.29%US$4.39MMay 31, 2026
First Trust Small Cap Growth AlphaDEX Fund688K0.27%US$3.41MJul 31, 2026
Schwab Small-Cap Index Fund594K0.24%US$2.94MJul 31, 2026
Fidelity Total Market Index Fund450K0.18%US$2.72MMay 31, 2026
Master Small Cap Index Series436K0.17%US$2.22MJun 30, 2026
Hussman Strategic Market Cycle Fund400K0.16%US$2.04MJun 30, 2026
Fidelity Series Total Market Index Fund370K0.15%US$2.23MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF363K0.14%US$1.85MJun 30, 2026
Nuveen Small Cap Blend Index Fund324K0.13%US$1.6MJul 31, 2026
Small Company Growth Portfolio285K0.11%US$1.45MJun 30, 2026
Vanguard Market Neutral Fund279K0.11%US$1.42MJun 30, 2026
BlackRock Advantage Small Cap Growth Fund268K0.11%US$1.37MJun 30, 2026
EQ/2000 Managed Volatility Portfolio265K0.11%US$1.35MJun 30, 2026
Schwab Small-Cap Equity Fund258K0.10%US$1.28MJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares252K0.10%US$1.25MJul 31, 2026
Virtus Biotech Etf239K0.09%US$1.18MJul 31, 2026
Fidelity Small Cap Growth Index Fund229K0.09%US$1.17MJun 30, 2026
Vanguard Russell 2000 Growth Index Fund225K0.09%US$1.36MMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund225K0.09%US$1.11MJul 31, 2026
Thrivent Small Cap Value ETF211K0.08%US$1.07MJun 30, 2026
Nuveen Equity Index Fund189K0.08%US$934KJul 31, 2026
Strategic Advisers U.S. Total Stock Fund183K0.07%US$1.11MMay 31, 2026
LVIP Franklin Templeton Multi-Factor SMID Cap Equity Fund176K0.07%US$898KJun 30, 2026
LVIP State Street Small-Cap Index Fund173K0.07%US$884KJun 30, 2026
First Trust Small Cap Core AlphaDEX Fund171K0.07%US$847KJul 31, 2026
EQ/Small Company Index Portfolio158K0.06%US$807KJun 30, 2026
Fidelity Nasdaq Composite Index Fund148K0.06%US$897KMay 31, 2026
Schwab Total Stock Market Index Fund147K0.06%US$730KJul 31, 2026
Schwab U.S. Broad Market ETF144K0.06%US$872KMay 31, 2026
Fidelity ZERO Total Market Index Fund135K0.05%US$668KJul 31, 2026
Vanguard Balanced Index Fund124K0.05%US$634KJun 30, 2026

This page holds 50 of 167 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Bishop John E
Officer: See Remarks
Sale17,281USD 3.86US$66,705Aug 21, 2026
Bishop John E
Officer: See Remarks
Sale2,469USD 3.86US$9,530Aug 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale15,009USD 3.86US$57,935Aug 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale15,976USD 3.86US$61,667Aug 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale8,411USD 3.86US$32,466Aug 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale19,178USD 3.86US$74,027Aug 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale3,486USD 3.86US$13,456Aug 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale3,089USD 3.86US$11,924Aug 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale2,430USD 3.86US$9,380Aug 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale1,734USD 3.86US$6,693Aug 21, 2026
All 45 trades
TradeTradeSharesPriceValueDate
Kelliher Mike
Officer: Chief Business Officer
Sale3,104USD 3.86US$11,981Aug 21, 2026
Kelliher Mike
Officer: Chief Business Officer
Sale2,652USD 3.86US$10,237Aug 21, 2026
Kelliher Mike
Officer: Chief Business Officer
Sale2,002USD 3.86US$7,728Aug 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale2,598USD 3.86US$10,028Aug 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale3,389USD 3.86US$13,082Aug 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale2,575USD 3.86US$9,940Aug 21, 2026
Reilly Joseph James
Officer: See Remarks
Sale2,872USD 3.86US$11,086Aug 21, 2026
Reilly Joseph James
Officer: See Remarks
Sale1,110USD 3.86US$4,285Aug 21, 2026
Brady James Parker
Officer: Chief Human Resources Officer
Sale1,976USD 3.86US$7,627Aug 21, 2026
Brady James Parker
Officer: Chief Human Resources Officer
Sale13,160USD 3.86US$50,798Aug 21, 2026
Hohenleitner Susan
Officer: Chief Financial Officer
Sale1,558USD 3.86US$6,014Aug 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale41,668USD 5.06US$211KJul 15, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale81,898USD 5.99US$491KJun 18, 2026
Raab Michael
Director, Officer: President & CEO
Sale41,666USD 5.67US$236KJun 15, 2026
Bishop John E
Officer: See Remarks
Sale2,306USD 6.27US$14,459May 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale14,933USD 6.27US$93,630May 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale7,861USD 6.27US$49,288May 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale17,926USD 6.27US$112KMay 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale14,028USD 6.27US$87,956May 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale1,503USD 6.27US$9,424May 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale2,157USD 6.27US$13,524May 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale1,911USD 6.27US$11,982May 21, 2026
Williams Laura A
Officer: Chief Patient Officer
Sale1,418USD 6.27US$8,891May 21, 2026
Kelliher Mike
Officer: Chief Business Officer
Sale2,900USD 6.27US$18,183May 21, 2026
Kelliher Mike
Officer: Chief Business Officer
Sale1,870USD 6.27US$11,725May 21, 2026
Kelliher Mike
Officer: Chief Business Officer
Sale2,478USD 6.27US$15,537May 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale3,166USD 6.27US$19,851May 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale2,427USD 6.27US$15,217May 21, 2026
Foster Eric Duane
Officer: Chief Commercial Officer
Sale2,405USD 6.27US$15,079May 21, 2026
Reilly Joseph James
Officer: See Remarks
Sale2,683USD 6.27US$16,822May 21, 2026
Reilly Joseph James
Officer: See Remarks
Sale1,036USD 6.27US$6,496May 21, 2026
Brady James Parker
Officer: Chief Human Resources Officer
Sale1,846USD 6.27US$11,574May 21, 2026
Hohenleitner Susan
Officer: Chief Financial Officer
Sale1,455USD 6.27US$9,123May 21, 2026
Raab Michael
Director, Officer: President & CEO
Sale41,666USD 6.28US$262KMay 15, 2026
Raab Michael
Director, Officer: President & CEO
Sale41,668USD 6.29US$262KApr 15, 2026

Big stakes

StakeStakeSharesDateFiling
Rubric Capital Management LP6.56%16.2MJun 30, 2026Schedule 13G
Tang Capital Management LLC5.70%14.3MNov 9, 2026Schedule 13G
Millennium Management LLC5.70%14.2MJun 30, 2026Schedule 13G
State Street Corp5.50%13.6MMar 31, 2026Schedule 13G
Janus Henderson Group PLC3.40%8.37MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Mott
Other companies: Novavax, Inc. (Director · Since at least Jun 16, 2020); Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Nightstar Therapeutics PLC (Director · Jan 1, 2019 – Jun 7, 2019 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jul 1, 2024 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Omthera Pharmaceuticals Inc (Director · Apr 11, 2013 – Jul 18, 2013 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past); Medimmune Inc (Vice Chair. of the Board, CEO, Director · Feb 23, 2006 – Jun 18, 2007 · Past)
Chairman · Since at least Jun 18, 2014
Annalisa Jenkins
Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Serina Therapeutics, Inc. (Director · Nov 27, 2018 – Jun 21, 2021 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past)
Director · Apr 20, 2015 – Jun 13, 2019 · Past
John Bishop
Other companies: Lyra Therapeutics, Inc. (Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Veracyte, Inc. (Director · Dec 1, 2014 – Jul 17, 2023 · Past); Cepheid (Chairman of the Board and CEO, Director · Feb 26, 2009 – Nov 4, 2016 · Past); Conceptus Inc (Director · Feb 25, 2009 – Jun 5, 2013 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past)
Chief Technical and Quality Officer · Since at least Aug 1, 2025
Richard Rodgers
Other companies: Novavax, Inc. (Director · Since at least Oct 29, 2022); Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jul 18, 2023 · Past); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past)
Director · Since at least Jun 18, 2014
Edward R. Conner
Other companies: Jade Biosciences, Inc. (Chief Medical Officer · Since Apr 22, 2026); Third Harmonic Bio Inc. (Chief Medical Officer · Sep 14, 2022 – Jan 15, 2025 · Past); Enliven Therapeutics, Inc. (Director · Apr 22, 2020 – Jun 2, 2022 · Past); Audentes Therapeutics Inc (SVP, Chief Medical Officer · Jul 15, 2019 – Jan 15, 2020 · Past); Sangamo Therapeutics, Inc. (Sr. VP & Chief Medical Officer · Nov 30, 2016 – Jan 24, 2019 · Past)
Chief Medical Officer · Since at least Aug 1, 2025
Merdad Parsey
Other companies: ArriVent BioPharma, Inc. (Director · Since at least Apr 28, 2025); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jun 5, 2024 · Past); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past)
Director · Since at least Apr 28, 2025
Susan Rodriguez
Other companies: Monopar Therapeutics Inc. (Chief Commercial and Strategy Officer · Since at least Mar 2, 2026); Avadel Pharmaceuticals PLC (Chief Operating Officer · Since at least May 13, 2025); Veradigm Inc. (Director · Since at least Feb 17, 2023); Heron Therapeutics, Inc. (Director · Sep 20, 2021 – Jan 31, 2025 · Past)
Chief Commercial Officer · May 18, 2020 – May 21, 2024 · Past
Gordon Ringold
Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); Alexza Pharmaceuticals Inc (Director · Mar 8, 2006 – Jun 21, 2016 · Past); Maxygen Inc (Director · Jan 3, 2006 – Jun 6, 2012 · Past)
Director · Jun 18, 2014 – Jun 9, 2020 · Past
Muna Bhanji
Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Veracyte, Inc. (Director · Since at least Mar 19, 2021); Cytokinetics, Incorporated (Director · Since at least Feb 17, 2021)
Director · Since at least Mar 11, 2021
Michael Raab
Other companies: Tempest Therapeutics, Inc. (Director · Since at least Jun 25, 2021); Amicus Therapeutics Inc (Director · Since at least Jun 9, 2016)
President & CEO, Director · Since at least Jan 19, 2017
All 41 people
PersonSeat
Onaiza Cadoret-Manier
Other companies: Ventyx Biosciences Inc (Director · Since at least Jan 11, 2023); Ionis Pharmaceuticals, Inc. (EVP,Chf GL Pdt Str & Oper Ofc · Jan 9, 2020 – Feb 2, 2024 · Past)
Director · Since at least Mar 12, 2020
Robert Bazemore
Other companies: Akari Therapeutics PLC (Director · Since at least Sep 17, 2024); Nuvation Bio Inc. (Director · Since at least Sep 3, 2024)
Director · Since at least Jun 14, 2024
Elizabeth Grammer
Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Jul 13, 2023)
See Remarks · Since at least Jun 18, 2014
Justin Renz
Other companies: Zevra Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 5, 2026)
Chief Financial Officer · Since at least May 20, 2022
Laura Williams
Other companies: Enliven Therapeutics, Inc. (Director · Jun 29, 2021 – Jun 2, 2022 · Past)
Chief Patient Officer Emeritus · Since at least Jun 15, 2022
Michael Kelliher
Other companies: Capricor Therapeutics, Inc. (Director · Since at least Jan 5, 2026)
Chief Business Officer · Since at least May 20, 2025
Peter G Schultz
Other companies: Symyx Technologies Inc (Director · Jan 3, 2006 – Dec 31, 2006 · Past)
Director · Jun 18, 2014 – Jun 11, 2015 · Past
Reginald Seeto
Other companies: CareDx, Inc. (See Remarks, Director · Nov 26, 2018 – Oct 2, 2023 · Past)
Chief Operating Officer · Oct 22, 2016 – Jan 16, 2018 · Past
William C Bertrand Jr
Other companies: Adaptimmune Therapeutics PLC (Chief Operating Officer · Since at least Mar 15, 2017)
Director · Since at least Jun 2, 2016
Caitlin LowieArdelyx Investor Relations and Corporate · Since at least Feb 24, 2026
David P RosenbaumChief Development Officer · Jun 18, 2014 – Nov 20, 2024 · Past
Dominique CharmotChief Scientific Officer, Director · Jun 18, 2014 – Jun 18, 2014 · Past
Eric Duane FosterChief Commercial Officer · Since at least May 20, 2025
Felecia EttenbergChief Legal Officer · Since at least Apr 20, 2026
Geoffrey A BlockDirector · Jun 15, 2022 – Jun 15, 2023 · Past
James Parker BradyChief Human Resources Officer · Since at least Jun 18, 2025
Jamie BradyChief Human Resources Officer · Since at least Aug 4, 2025
Jeffrey W JacobsChief Scientific Officer · Jun 18, 2014 – Nov 22, 2021 · Past
Joseph James ReillySee Remarks · Since at least Nov 15, 2024
Keith SantorelliSee Remarks · Mar 12, 2020 – Mar 12, 2020 · Past
Lindsey ManuelAssociate Director, Corporate Communications · Since at least Nov 3, 2026
Lisa CaperelliSVP, Investor Relations & Corporate Communications · Since at least Nov 3, 2026
Mike KelliherChief Business Officer · Since at least Aug 4, 2025
Mike RaabPresident & Chief Executive Officer · Since at least Aug 25, 2026
Narani ArasaratnamVP, Corporate Controller · Nov 3, 2014 – Jan 15, 2016 · Past
Rajani DinavahiChief Medical Officer · Since at least Apr 1, 2026
Robert BlanksSee Remarks · May 20, 2022 – Nov 20, 2024 · Past
Robert Ora FelschSee Remarks · Mar 10, 2022 – Aug 20, 2024 · Past
Sue HohenleitnerChief Financial Officer · Since at least Feb 5, 2026
Susan HohenleitnerChief Financial Officer · Since at least Nov 4, 2025
William A. BertrandDirector · Since at least Jun 18, 2026

Open People

Log in to ask 6ix AI your own questions about Ardelyx, Inc.